Form 8-K - Current report:
SEC Accession No. 0001213900-25-041582
Filing Date
2025-05-09
Accepted
2025-05-09 17:00:08
Documents
16
Period of Report
2025-05-08
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0241600-8k_actinium.htm   iXBRL 8-K 29317
2 LETTER FROM MARCUM DATED MAY 08, 2025 ea024160001ex16-1_actinium.htm EX-16.1 3289
3 GRAPHIC ex16-1_001.jpg GRAPHIC 16405
4 GRAPHIC ex16-1_002.jpg GRAPHIC 6681
  Complete submission text file 0001213900-25-041582.txt   240091

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE atnm-20250508.xsd EX-101.SCH 3032
6 XBRL LABEL FILE atnm-20250508_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE atnm-20250508_pre.xml EX-101.PRE 22370
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0241600-8k_actinium_htm.xml XML 3687
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 25931415
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)